adplus-dvertising
Connect with us

Health

An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race – Yahoo Canada Finance

Published

 on



<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The gradual relaxation of coronavirus restrictions is stoking hopes for an economic rebound, with the biotechnology industry riding a wave of expectations in the hunt for an effective COVID-19 treatment.” data-reactid=”16″>The gradual relaxation of coronavirus restrictions is stoking hopes for an economic rebound, with the biotechnology industry riding a wave of expectations in the hunt for an effective COVID-19 treatment.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy. Worldwide, there are nearly 5 million positive cases and over 300,000 have been killed by the virus.” data-reactid=”17″>Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy. Worldwide, there are nearly 5 million positive cases and over 300,000 have been killed by the virus.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="With so much at stake, the global pipeline has become an intense space race for the new era. Nations are locked in an intense effort to demonstrate their biotech capabilities in the worldwide fight against COVID-19.” data-reactid=”18″>With so much at stake, the global pipeline has become an intense space race for the new era. Nations are locked in an intense effort to demonstrate their biotech capabilities in the worldwide fight against COVID-19.

In collaboration with branches of the U.S. Health and Human Services (HHS) and National Institute of Health (NIH), small and large drug companies have been working on vaccines.

300x250x1

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="For now, the furthest along are Moderna (MRNA) and Pfizer (PFE), both of which are using messenger RNA technology— a newer technology that doesn’t exist in the current drug market. Both have entered human clinical trials. Abroad, all eyes are on China’s CanSino, and a project underway at Oxford University in the U.K.” data-reactid=”20″>For now, the furthest along are Moderna (MRNA) and Pfizer (PFE), both of which are using messenger RNA technology— a newer technology that doesn’t exist in the current drug market. Both have entered human clinical trials. Abroad, all eyes are on China’s CanSino, and a project underway at Oxford University in the U.K.

Currently, “there are at least a hundred horses in the race, and we’ve got some leaders up front,” Marc Poznansky, the director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, told Yahoo Finance recently.

He added that it was “unprecedented to have that many platforms at play putting a product into testing to try to get to first in human” trials.

This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. - After conclusive results on mice, Thai scientists from the centre have begun testing a COVID-19 novel coronavirus vaccine candidate on monkeys, the phase before human trials. (Photo by Mladen ANTONOV / AFP) (Photo by MLADEN ANTONOV/AFP via Getty Images)

View photos

This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. – After conclusive results on mice, Thai scientists from the centre have begun testing a COVID-19 novel coronavirus vaccine candidate on monkeys, the phase before human trials. (Photo by Mladen ANTONOV / AFP) (Photo by MLADEN ANTONOV/AFP via Getty Images)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The World Health Organization is tracking the growing field, where less than a dozen of which have entered clinical trials. Some are being developed in coordination with governments, while others are through industry or academic collaboration.” data-reactid=”43″>The World Health Organization is tracking the growing field, where less than a dozen of which have entered clinical trials. Some are being developed in coordination with governments, while others are through industry or academic collaboration.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The expectations have placed an unprecedented demand on a “pandemic market” that could eventually be valued anywhere between $10 to $30 billion, analysts at Morgan Stanley said last week. But an effective treatment is unlikely until the first half of 2021 at the earliest, with many health experts cautioning that aggressive development timelines are “aspirational” at best.” data-reactid=”44″>The expectations have placed an unprecedented demand on a “pandemic market” that could eventually be valued anywhere between $10 to $30 billion, analysts at Morgan Stanley said last week. But an effective treatment is unlikely until the first half of 2021 at the earliest, with many health experts cautioning that aggressive development timelines are “aspirational” at best.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Still, pharmaceutical companies are repurposing existing drugs and trying to find treatments for those currently sick with the virus, with investors trying to determine the winners and losers of this high stakes race.” data-reactid=”45″>Still, pharmaceutical companies are repurposing existing drugs and trying to find treatments for those currently sick with the virus, with investors trying to determine the winners and losers of this high stakes race.

<h2 class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="A ‘Warp Speed’ race” data-reactid=”46″>A ‘Warp Speed’ race

There are over 1.5 million coronavirus cases in the U.S. (Graphic: David Foster/Yahoo Finance)There are over 1.5 million coronavirus cases in the U.S. (Graphic: David Foster/Yahoo Finance)

View photos

There are over 1.5 million coronavirus cases in the U.S. (Graphic: David Foster/Yahoo Finance)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The world’s two largest economies are engaged in fierce competition to find a vaccine. China is moving to bolster its nascent biotech industry and expand its reach globally, while the U.S. is fighting to balance urgency with safety and serving the needs at home first.” data-reactid=”67″>The world’s two largest economies are engaged in fierce competition to find a vaccine. China is moving to bolster its nascent biotech industry and expand its reach globally, while the U.S. is fighting to balance urgency with safety and serving the needs at home first.

In order to winnow down the widening field of vaccine candidates, the U.S. has rolled out Operation Warp Speed, using $3 billion appropriated by Congress to fund vaccine development. Meanwhile, the U.S. Food and Drug Administration is working closely with drug companies to follow expedited timelines for clinical trials, as drug companies aim to produce billions of doses as soon as a candidate is viable.

Global collaborations through the WHO, and a concerted effort in the European Union are also at play. WHO officials also recently said they are working with both the public and private sector in India, which has a massive capacity for vaccine production, to produce the vaccines for the world.

Private institutions, like the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness (CEPI), are also pursuing candidates.

In the U.S., Moderna has received $483 million in funding from HHS’s Biomedical Advanced Research and Development Authority (BARDA), and is developing its treatment in collaboration with the National Institute of Allergy and Infectious Diseases, the agency led by Dr. Anthony Fauci.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Recently, Moderna has tapped the capital market in an effort to produce a billion vaccine doses per year, which it is doing in partnership with Swiss manufacturer Lonza Group.” data-reactid=”76″>Recently, Moderna has tapped the capital market in an effort to produce a billion vaccine doses per year, which it is doing in partnership with Swiss manufacturer Lonza Group.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Separately, Pfizer has partnered with German biotech BioNTech to develop its own vaccine, pivoting from their work together on a flu treatment.” data-reactid=”77″>Separately, Pfizer has partnered with German biotech BioNTech to develop its own vaccine, pivoting from their work together on a flu treatment.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Sanofi (SNY) and GlaxoSmithKline (GSK) are engaged in a joint effort in the race; meanwhile, Johnson &amp; Johnson (JNJ) are among the larger pharmaceutical contenders, and have also gotten BARDA backing.” data-reactid=”78″>Sanofi (SNY) and GlaxoSmithKline (GSK) are engaged in a joint effort in the race; meanwhile, Johnson & Johnson (JNJ) are among the larger pharmaceutical contenders, and have also gotten BARDA backing.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Two smaller biotechs, Inovio (INO) and Novavax (NVAX), have received funding from CEPI and are also working on vaccines. Inovio, which had previously worked on another coronavirus vaccine, was the second company in the U.S. to enter into clinical trials with its candidate. While data on the clinical trials are pending, pre-clinical data showed positive results in animal studies.” data-reactid=”79″>Two smaller biotechs, Inovio (INO) and Novavax (NVAX), have received funding from CEPI and are also working on vaccines. Inovio, which had previously worked on another coronavirus vaccine, was the second company in the U.S. to enter into clinical trials with its candidate. While data on the clinical trials are pending, pre-clinical data showed positive results in animal studies.

China and the world

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="China has a young biotech industry, growing significantly in the last few years with government support, that is aggressively trying to prove itself to the world. That includes committing to supporting WHO and plans to share its vaccine with the world.” data-reactid=”81″>China has a young biotech industry, growing significantly in the last few years with government support, that is aggressively trying to prove itself to the world. That includes committing to supporting WHO and plans to share its vaccine with the world.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CanSino Biologics, along with partner Beijing Institute of Biotechnology, are leading the world with a vaccine to be approved by fall 2020 in China. The company recently hired a former Sanofi executive to run its international business operations.” data-reactid=”82″>CanSino Biologics, along with partner Beijing Institute of Biotechnology, are leading the world with a vaccine to be approved by fall 2020 in China. The company recently hired a former Sanofi executive to run its international business operations.

Two other leading contenders are Sinopharm — which is working on clinical trials with both the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products — and another from Sinovac.

Meanwhile, the U.K. has also invested in a vaccine candidate coming out of Oxford University, which also plans to supply its treatment globally. The university is partnering with the pharmaceutical giant AstraZeneca and the Serum Institute in India to distribute its potential vaccine.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The U.K. government is also investing a new production plant to ensure mass-production by next summer.” data-reactid=”85″>The U.K. government is also investing a new production plant to ensure mass-production by next summer.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Health

COVID-19 and flu activity in Manitoba drops again

Published

 on

COVID-19 and influenza activity is on a steady decline in Manitoba, with hospital admissions and new cases dropping significantly for the third straight week.

There were seven people hospitalized for COVID-19 from Jan. 15-21, the latest provincial surveillance data says. The previous reporting week had 28 hospitalizations.

Admissions to intensive care units, due to severe cases, also went down from six to three in that same span.

The total number of deaths related to the virus increased by 15 in the most recent surveillance report, compared to nine the previous week and 25 the week before that.

300x250x1

There were just 59 new COVID-19 cases detected in the latest report, a more than 50 per cent decline from the 122 in the Jan. 8–14 report. Those numbers, though, are considered significant undercounts due to limited testing offered by Public Health. The province does not track results from home tests.

The weekly test positivity rate for COVID-19 went down to 11.3 per cent from 12.3 per cent in the previous report.

Flu test positivity falls below 1%

As for Influenza A, the primary flu strain this season, the number of cases detected in the current surveillance week is 10, versus 18 the prior week.

A total of two people were admitted to hospital for flu symptoms, with no ICU cases, which is identical to the previous week. Two additional deaths were attributed to the flu in the report for Jan. 15-21, compared to one the previous week.

The current weekly test positivity for Influenza A is 0.8 per cent, whereas it was 1.9 per cent a week ago.

The national rate is 1.3 per cent.

Other respiratory viruses continue to circulate as well, but the test positivity rate for and detection of respiratory syncytial virus (RSV) have both decreased as well.

The number of detected RSV cases in the latest report is 105 (down from 131) and the test positivity rate is 8.3 per cent (down from 8.7).

Wastewater surveillance data indicates sustained activity of COVID-19 in Winnipeg and Brandon but at lower levels.

The next reporting date is Feb. 3.

728x90x4

Source link

Continue Reading

Health

Study Establishes Connections Between Emotional Maltreatment, Psychiatric Disorders

Published

 on

New study results published in Child Maltreatment have found links between emotional maltreatment, also known as psychological violence, and psychiatric disorders in childhood and adolescence.

Emotional maltreatment can be challenging to recognize and record, both in research and in practice. Navigating that challenge resulted in an elaborate study conducted by researchers at the Faculty of Medicine in the University of Leipzig, with the goal of understanding the psychological effects that abuse, neglect, and emotional maltreatment have on children and adolescents.

Examples of emotional abuse include when parents subject their children to extreme humiliation, threaten to put them in foster care, or blame children for their own psychological distress or suicidal thoughts. Physical violence also plays a crucial role in the development of psychiatric disorders.

“Our study findings clearly show that emotional maltreatment is not only a very common form of maltreatment, but also one with psychiatric consequences that are similar to or even more severe than other forms of maltreatment,” said study leader and last author Lars White, PhD, in a press release.

300x250x1

In their study of 778 children, researchers found that 80% of the children and adolescents who reported having been mistreated had also experienced emotional maltreatment. This makes emotional maltreatment the most common form of child abuse.

Additionally, the investigators were able to show that of all forms of maltreatment, psychological violence had the strongest effects on the psyche of the children and adolescents, even in comparison with forms of maltreatment that generally receive more attention, such as physical abuse. In younger children between 3 and 8 years of age, emotional maltreatment led primarily to behavioral problems, whereas in older children it was more likely to lead to depression and anxiety disorders.

To conduct the study, family data were collected with extensive interviews and the researchers analyzed files from youth welfare offices for evidence of maltreatment experiences. The sample consisted of 306 children and adolescents with an experience of maltreatment and 472 participants without these experiences. Among other sources, participants were recruited via the residents’ registration offices, daycare centers, child and youth psychiatry centers, and youth welfare offices in Leipzig and Munich.

“We are particularly grateful for the support of the youth welfare offices because this enabled us to recruit families for the study who have had extremely difficult experiences and who are otherwise difficult to reach for research projects,” said lead author Jan Keil, DrPhil, in the press release.

The findings illustrate that the risk of developing psychiatric disorders after maltreatment is already heightened in early and middle childhood, which underlines the need for early intervention. The authors said emotional maltreatment should be understood as a dimension of abuse unto itself and should be a key focus in both research and treatment efforts.

“We need to educate parents so that they take the child’s perspective more often,” White said in the press release. “As recently as 30 years ago, the commonly held view was that children should be left to cry and that what they experience in childhood they forget anyway. But increasingly, there is a complete shift in attitudes and an appreciation that we need to reach out to the youngest children when they are showing difficult emotions, such as being angry or sad.”

REFERENCE

From emotional maltreatment to psychiatric disorders in childhood and adolescence. News release. EurekAlert; January 12, 2023. Accessed January 17, 2023. https://www.eurekalert.org/news-releases/976487

728x90x4

Source link

Continue Reading

Health

Leaders in discovery: five USask researchers honoured with top provincial health awards

Published

 on

“Dr. Gerdts’ scientific and leadership accomplishments throughout his illustrious career make him most deserving of this award and recognition. We are grateful for his leadership of VIDO, particularly during the challenging times of the COVID-19 pandemic. He was able to grow and strengthen Canada’s pandemic response and was an integral part in creating Canada’s Centre for Pandemic Research,” said USask Vice-President Research Baljit Singh. “We are grateful for his ongoing commitment to our One Health Signature Area of Research and for inspiring the next generation of scientific leaders.”

Beyond his impressive professional achievements of publications and citations, Gerdts has been a mentor and leader in One Health, which recognizes the integral connections between human, animal, and environmental health. At the institutional level, he has been a champion for One Health as a signature area of research at USask. On the international stage, he co-led the Natural Sciences and Engineering Research Council of Canada (NSERC)-funded Integrated Training Program in Infectious Diseases, Food Safety and Public Policy, training more than 200 young researchers from 15 countries.

“This award is recognition of the many colleagues and collaborators I have worked with over the years, including an outstanding group of individuals here at VIDO,” said Gerdts. “I am excited to continue to develop solutions for emerging diseases of humans and animals. The support from SHRF and other funders over the years has helped to make this vision reality.”

With 91 grants totaling more than $117 million as principal investigator, more than $79 million as co-applicant and over $10 million in contract research, Gerdts has led the development of several vaccines and novel adjuvants—ingredients that help create a stronger immune response—for people and animals.

300x250x1

His work helped to develop a universal protocol for vaccination of pregnant women to improve the health of newborn babies, and as a result, pregnant women now routinely receive the pertussis (whooping cough) vaccine to protect their newborns against the disease. Gerdts’ research focusing on the fetal immune system development was published in Nature Medicine, and his work on a single-immunization vaccine platform for neonates continues with research into a vaccine for pertussis and respiratory syncytial (RSV), which is undergoing production optimization so it can be ready for production in VIDO’s manufacturing facility and used in human clinical trials.

Under his leadership VIDO has experienced enormous growth, including the completion of its vaccine manufacturing facility that strengthens Canada’s production capacity, positioning VIDO as Canada’s Centre for Pandemic Research. He has also played an integral role in drawing top talent from around the globe to work and live in Saskatchewan, while at the same time elevating the province’s scientific reputation.

Since the beginning of the pandemic, Gerdts has demonstrated creative thinking and a keen ability to successfully bring together funders and interdisciplinary collaborators. His over 250 media interviews and presentations about COVID-19 are examples of his skills as a trusted scientific communicator.

Gerdts is among five USask researchers recognized by the provincial funding agency as part of its annual Santé Awards honouring health research excellence in Saskatchewan.

“We are proud of our researchers who have received these prestigious awards,” said Singh. “They are confronting the world’s greatest challenges head on through creativity and collaboration. Their collective impact includes discoveries for improved mental health and wellness, hope for new treatments for drug-resistant infections, and the expertise that will influence how our decision-makers will shape an accessible and culturally responsive healthcare system for the people of Saskatchewan.”

728x90x4

Source link

Continue Reading

Trending